Építés alatt – nem éles oldal
Belépés
Résztvevőt keres2. fázis

BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers

A legfontosabb adatok

Ki végzi
Blue Blood Biotech Corp.
Hol
Tajvan5 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
96 fő, tervezett
Kezdés
2024. máj. 1.
Várható befejezés
2028. dec. 31.
A vizsgálat típusa
Beavatkozással járó, 3 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • BB-101
A regiszteradat frissítve
2026. október 2.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with type 1 or type 2 diabetes who have a foot or lower leg ulcer that has not healed. It tests a liquid called BB-101, put on the ulcer, against a placebo.

Életkor
20 years or older
Nem
All sexes
A betegség stádiuma
At least one diabetic ulcer below the knee. It has not healed for 4 weeks or more despite care. Size 0.5 cm2 to 10 cm2. Wagner Grade 1 to Grade 2. No signs of infection. Blood flow to the leg must be good enough.
Korábbi kezelés
Must be under a doctor's care for diabetes. No growth factors such as becaplermin on the ulcer, no systemic corticosteroids, immunosuppressive agents, radiation or chemotherapy, and no other trial drug or device within 4 weeks before screening. No skin grafts, skin substitutes or hyperbaric oxygen therapy within 2 weeks. No topical antimicrobials or enzyme cleaning of the ulcer within 7 days.
Biomarker vagy leletérték
HbA1c ≤ 12% (108 mmol/mol). ALT and AST ≤ 2 × ULN. Serum creatinine ≤ 3 mg/dL (265 µmol/L). ANC ≥ 1,500 cells/μL, WBC ≥ 3,000 cells/μL, platelets ≥ 100,000 counts/μL. Hemoglobin ≥ 10 g/dL for men, ≥ 9 g/dL for women. Women need a negative pregnancy test.

A részvétel fő kizáró okai

  • Infected ulcer, cellulitis, gangrene, or active bone infection needing antibiotics
  • Ulcer that shrank or grew by at least 30% after 2 weeks of standard care
  • Current cancer or past cancer, apart from some treated skin or cervical cancers
  • Sickle cell disease, vasculitis, or other conditions that slow healing
  • HIV-positive, breastfeeding, or drug or alcohol abuse

A regiszter feltételei, szó szerint

Mind a 21 feltétel megnézéseKevesebb

Ki vehet részt

  • Male or female, at least 20 years of age (inclusive) at the date of Screening
  • Subject or legally authorized representative who is able to understand the nature of this study and accepts to enter the study by signing written informed consent
  • Subject agrees to comply with ulcer care regimen for the duration of the study and is willing to return for all mandatory visits as defined in the protocol
  • Subject with Type 1 or Type 2 diabetes mellitus (criteria for the diagnosis of diabetes mellitus per American Diabetes Association) and is under the care of a physician for the management of diabetes mellitus
  • Subject with glycosylated hemoglobin (HbA1c) ≤ 12%
  • Subject with at least one diabetic foot ulcer meets the following criteria at Screening; Visit:
  • Located below knees; ii. Not healing for ≥ 4 weeks prior to Screening Visit despite appropriate care; iii. Ulcer size of ≥ 0.5 cm2 to ≤ 10 cm2 measured by the electronic measuring device following sharp debridement (if necessary) at Screening Visit and reconfirmed at Randomization Visit; iv. The largest ulcer will be selected as target ulcer. If ≥ 2 ulcers have the largest size, the one with the worst grade by Wagner Classification will be selected. If ≥ 2 ulcers have the largest size and grade, the one with longest duration will be selected; v. The target ulcer is classified as Grade 1 to Grade 2 according to Wagner Classification System for diabetic foot ulcer; vi. The target ulcer should be without clinical signs and symptoms of infection
  • Subject with adequate circulation to the affected lower limb, as demonstrated by at least one of the following criteria: i. Dorsum transcutaneous oximetry (TcPO2) ≥ 30 mmHg ii. Ankle brachial pressure index (ABPI) ≥ 0.7 iii. Absolute toe blood pressure > 30 mmHg iv. Doppler ultrasonography showed < 75% stenosis in the lower extremity arteries
  • Subject with adequate hepatic (ALT and AST ≤ 2 × ULN) and renal function (Serum creatinine ≤ 3 mg/dL)
  • Subject with adequate hematology function:; Absolute neutrophil count (ANC) ≥ 1,500 cells/μL ii. Total white blood cell (WBC) ≥ 3,000 cells/μL iii. Platelets ≥ 100,000 counts/μL iv. Hemoglobin ≥ 10 g/dL for male, ≥ 9 g/dL for female
  • Female subjects show negative serum pregnancy test results within 28 days prior to the first study treatment
  • All male subjects and female subjects with child-bearing potential (between puberty and 2 years after menopause) should use at least any one of the appropriate contraception methods during dosing and for at least 4 weeks after stopping study treatment

Ki nem vehet részt

  • Purulent discharge; Subject with cellulitis or gangrene on the lower leg or foot with the target ulcer; Subject with active osteomyelitis, which requires systemic antibiotics. Systemic antibiotics must be complete or discontinued 1 week prior to Screening Visit; With target ulcer size decreased or increased by at least 30% after receiving 2 weeks of standard-of-care for diabetic foot ulcer before Randomization visit; Subject with another open ulcer < 2 cm away from target ulcer, on the same lower leg or foot; Subject with target ulcer caused primarily by etiologies not related to diabetes; Subject with target ulcers related to an incompletely healed amputation wound; Subject with any structural deformity of the lower leg or foot under study that would prevent off-loading of the target ulcer; subject with conditions which may interfere the off-loading effect may be excluded by the Investigators' judgment; Subject is scheduled to (or has received within 4 weeks prior to Screen Visit) receive any of the following medications or treatments:
  • Systemic corticosteroids (other than for inhalation), immunosuppressive agents, radiation therapy, or chemotherapeutic agents
  • Clinical signs and symptoms of infection of target ulcer assessed by clinical evaluation; The presence of infection is defined by ≥ 2 of the items presented as:
  • Platelet-derived product (e.g., becaplermin) or other growth factors on the target ulcer
  • Participation in a clinical trial of an investigational drug or device; Previous use of autologous graft or allogeneic graft, or dermal substitute or living skin equivalent (e.g., Dermagraft® or Apligraf® ) on the target ulcer or hyperbaric oxygen therapy within 2 weeks prior to Screening Visit; Use of any topical antimicrobials or enzymatic debridement treatment to treat the target ulcer within 7 days prior to Screening Visit; Subject with history of cancer or current cancer, with the exception of basal cell carcinoma, squamous cell carcinoma in situ of the skin, or cervical carcinoma in situ that has been treated with no evidence of recurrence, or squamous cell carcinoma of the skin that has been treated with no evidence of recurrence within 5 years prior to administration of any study agent; Vasculitis, connective tissue diseases, or any medical conditions known to impair ulcer healing, other than diabetes; Subject diagnosed with sickle cell disease; Subject with clinically significant electrocardiogram (ECG) abnormality, as determined by the Investigator; Poor nutritional status (serum albumin < 2.5 g/dL); C-reactive protein (CRP) > 50 mg/dL; Subject had a history of drug abuse or alcohol abuse according to the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) criteria; Patient with positive result of Human immunodeficiency virus (HIV); Female subject in lactation during the study period; Subject with underlying medical, mental or psychological conditions that would impair the treatment compliance, or in the opinion of the Investigator would not permit to participate in the study
  • Local swelling or induration
  • Erythema > 0.5 cm around wound
  • Local tenderness or pain
  • Local increased warmth

Ez a vizsgálat jelenleg itt érhető el: Tajvan.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a randomized, double-blinded, vehicle-controlled, parallel, phase II study to evaluate the efficacy and safety of topical BB-101 for the treatment of diabetic lower leg and foot ulcer.

A vizsgálat 3 csoportja

  • High Dose Dosing GroupMár használt kezelés, összehasonlításként

    High Dose BB-101 topical solution will be applied on the target lower leg or foot ulcer once a for for 4 consecutive weeks.

    Kezelés: BB-101

  • Low Dose Dosing GroupMár használt kezelés, összehasonlításként

    Low Dose BB-101 topical solution will be applied on the target lower leg or foot ulcer once a for for 4 consecutive weeks.

    Kezelés: BB-101

  • Placebo Dosing GroupPlacebo, összehasonlításként

    Placebo will be applied on the target lower leg or foot ulcer once a for for 4 consecutive weeks.

    Kezelés: BB-101

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Phase II Study to Evaluate the Efficacy and Safety of Topical BB-101 for the Treatment of Diabetic Lower Leg and Foot Ulcers
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
A regiszteradat frissítve
2026. október 2.